Nektar(US:NKTR) TMX Newsfile·2026-03-15 12:59Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nektar Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and trial results [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Nektar between February 26, 2025, and December 15, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Nektar, with a deadline of May 5, 2026, for investors to seek the role of lead plaintiff [2]. Group 2: Allegations Against Nektar - The complaint alleges that Nektar and its executives made false and misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity [4]. - Nektar's press release on December 16, 2025, revealed that the Phase 2b REZOLVE-AA trial failed to reach statistical significance due to the inclusion of ineligible patients [5]. Group 3: Market Impact - Following the announcement of the trial results, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share on December 16, 2025 [6].